Insulet Corporation  

(Public, NASDAQ:PODD)   Watch this stock  
Find more results for podd
37.05
-0.55 (-1.46%)
Real-time:   12:39PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 36.79 - 37.78
52 week 30.04 - 51.31
Open 37.53
Vol / Avg. 192,878.00/412,004.00
Mkt cap 2.09B
P/E     -
Div/yield     -
EPS -1.07
Shares 55.88M
Beta 0.85
Inst. own 113%
Nov 5, 2014
Q3 2014 Insulet Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 9, 2014
Insulet Corp at Morgan Stanley Healthcare Conference
Sep 3, 2014
Insulet Corp at Barrington Research Fall Investment Conference
Aug 14, 2014
Insulet Corp at Canaccord Genuity Growth Conference
Aug 7, 2014
Q2 2014 Insulet Corp Earnings Call
Aug 7, 2014
Q2 2014 Insulet Corporation Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -40.42% -18.20%
Operating margin -33.64% -11.79%
EBITD margin - -7.01%
Return on average assets -38.04% -18.51%
Return on average equity -116.54% -53.30%
Employees 478 -
CDP Score - -

Address

600 Technology Park Dr Ste 200
BILLERICA, MA 01821-4154
United States - Map
+1-978-6007000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insulet Corporation is engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (the OmniPod System). The OmniPod System is an insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the Company's handheld, wireless Personal Diabetes Manager (PDM). The OmniPod Insulin Management System is designed to provide people with insulin-dependent diabetes with a diabetes management solution which provides lifestyle and other benefits and to expand the use of continuous subcutaneous insulin infusion (CSII) therapy. The OmniPod operates up to 72 hours (but no more than 80 hours) after it is activated.

Officers and directors

Brian K. Roberts CPA Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
William Patrick Ryan Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
R. Anthony Anthony Diehl Esq. General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Peter Devlin Chief Commercial Officer
Age: 46
Bio & Compensation  - Reuters
Patrick J. Sullivan President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Sally W. Crawford Lead Independent Director
Age: 60
Bio & Compensation  - Reuters
Charles T Liamos Director
Age: 54
Bio & Compensation  - Reuters
Timothy J. Scannell Director
Age: 49
Bio & Compensation  - Reuters
John A. Fallon M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Daniel J. Levangie Independent Director
Age: 63
Bio & Compensation  - Reuters